Need support?
Connect live with Daiichi Sankyo AccessCentral4U
1-866-4-DSI-NOW (1-866-437-4669)
Mon – Fri, 8:00AM – 6:00PM ET, excluding holidays
VANFLYTA Access Central is now VANFLYTA4U. Our commitment to helping patients receive their prescribed VANFLYTA treatment remains the same. Learn More
×
Please see Full Prescribing Information, including Boxed WARNINGS, and Medication Guide.
This information is intended for US healthcare professionals and/or healthcare professionals involved in healthcare reimbursement only.
VANFLYTA Access Central is becoming
During this time, you may see both program names in use.
Daiichi Sankyo remains dedicated to helping patients find financial assistance and resources to receive their medications with confidence. VANFLYTA4U is here to provide support and information to help.
Need Support? 
close
Welcome to
Please select if you are a US Healthcare Professional or Patient
VANFLYTA® (quizartinib) Savings Program
The VANFLYTA Savings Program can help your patient with their out-of-pocket costs if they have commercial or private insurance.
Eligible patients may pay as little as $0 per prescription.
Qualifying patients may pay as little as $0 per prescription of VANFLYTA.
The patient must have commercial insurance coverage.
There are no income requirements for eligibility.
See below for full patient eligibility. Restrictions apply.
Easy enrollment
2 simple ways to enroll
The information provided on the Patient Enrollment Form will be used by the network specialty pharmacy to determine whether your patient is eligible for the VANFLYTA Savings Program. If your patient is eligible, the specialty pharmacy will automatically enroll the patient and call your patient to inform them.
OR
VANFLYTA Patient Savings Program Terms and Conditions.
This program is available to eligible patients with commercial insurance. Patients participating in government healthcare insurance programs are not eligible, including patients participating in Medicare, Medicaid, Medigap, TRICARE, Veterans Affairs (VA), Department of Defense (DoD), or any state-funded programs. Eligible patients will be automatically reenrolled in the program on an annual basis contingent upon the patients ability to meet requirements set forth by the program. Amount paid under the program are not eligible for reimbursement by any third party. Patients may be required to notify their insurance company of any benefits received under the program The program is not insurance. Patients can enroll up to 30 days after the first VANFLYTA treatment and utilize a retroactive enrollment period for assistance on dates of service that took place prior to enrollment. The practice or patient must call VANFLYTA4U for assistance on retroactive enrollment. Daiichi Sankyo, Inc, reserves the right to rescind, revoke, or amend the program at any time, without notice.
The completion and submission of coverage-related documentation are the responsibility of the patient and healthcare provider. Daiichi Sankyo, Inc. makes no representation or guarantee concerning coverage or reimbursement for any service or item. A completed Patient Enrollment Form includes signatures from both the physician and the patient. Before submitting, please ensure all required information is provided.
Uninsured, underinsured, or Medicare enrollees who are unable to meet their out-of-pocket costs may be eligible for the VANFLYTA® (quizartinib) Patient Assistance Program (PAP).
The VANFLYTA Patient Assistance Program may provide VANFLYTA at no cost for financially eligible patients who are uninsured or underinsured.
Do you have an uninsured or underinsured patient who needs financial assistance with their VANFLYTA treatment?
If so, simply fill out the Patient Enrollment Form and fax to either your selected network specialty pharmacy or, if utilizing your office-/hospital-based pharmacy, VANFLYTA4U. Your patient may also need to submit proof of income (W2, tax return, etc).
Basic Eligibility Requirements
To be eligible for the VANFLYTA Patient Assistance Program, your patient must:
- Have been prescribed VANFLYTA.
- Be a resident of the United States or Puerto Rico.
- Not have insurance, private or government, that covers VANFLYTA.
- Have an annual income at or below a certain level.
Medicare beneficiaries must:
- Not be eligible for, or enrolled in, the Low Income Subsidy (LIS) for Medicare Part D.
- Have spent at least 3% of their annual household income on prescription medicines in the current year.
VANFLYTA4U can provide more detailed information on qualifying. Uninsured patients are enrolled for 12 months from their approval date, whereas Medicare patients are enrolled through December 31 of the year in which they are approved. Patients may reapply for the program. Daiichi Sankyo, Inc. reserves the right to change or cancel the program immediately with respect to any patient, or in its entirety, at any time.
The completion and submission of coverage-related documentation are the responsibility of the patient and healthcare provider. Daiichi Sankyo, Inc. makes no representation or guarantee concerning coverage or reimbursement for any service or item. A completed Patient Enrollment Form includes signatures from both the physician and the patient. Before submitting, please ensure all required information is provided.
Patients with government insurance
If your patient has government insurance (such as Medicare or Medicaid), there are outside or third-party organizations, that may provide help with the cost of their medication. See Additional Support for a list of some of these organizations.
VANFLYTA® (quizartinib) QuickStart Program
Patients experiencing a coverage delay greater than 5 business days may be eligible for the VANFLYTA QuickStart Program.
Getting started
When filling out the Patient Enrollment Form, completing the optional QuickStart prescription section will help expedite this process.
Eligible patients can receive a 14-day supply at no cost (up to 1 refill).
Basic Eligibility Requirements
To be eligible, your patient must:
Be experiencing a coverage delay of greater than 5 business days AND:
Be new to VANFLYTA and have commercial or government insurance
OR
Be currently receiving VANFLYTA treatment and have commercial insurance
Additional terms and conditions apply.
The completion and submission of coverage-related documentation are the responsibility of the patient and healthcare provider. Daiichi Sankyo, Inc. makes no representation or guarantee concerning coverage or reimbursement for any service or item. A completed Patient Enrollment Form includes signatures from both the physician and the patient. Before submitting, please ensure all required information is provided.
VANFLYTA® (quizartinib) Distribution
VANFLYTA is available through a select network of Specialty Pharmacies and Specialty Distributors, to provide flexibility in site of dispensing. Office-, hospital-, or health system-based pharmacies that are REMS certified may order VANFLYTA from one of the network specialty distributors below for subsequent dispensing.
Specialty pharmacies*
Specialty distributors
BioCareSD
Phone: 1-800-304-3064
Fax: 1-602-850-6215
Cardinal Health Specialty Distribution
Phone: 1-866-677-4844
Cardinal Health Puerto Rico
Phone: 1-787-625-4200
Fax: 1-787-625-4398
Email: cuserv@cardinalhealth.com
McKesson Plasma and Biologics
Phone: 1-877-625-2566
Fax: 1-888-752-7626
McKesson Specialty Health
Phone: 1-855-477-9800
Fax: 1-800-800-5673
Morris & Dickson Specialty Distribution
Phone: 1-318-798-5295
Fax: 1-318-524-3096
*REMS certification is required for all Pharmacies. Please visit VANFLYTAREMS.com for more information.
Need Support?
Connect live with Daiichi Sankyo AccessCentral4U.
1-866-4-DSI-NOW (1-866-437-4669)
Mon – Fri, 8:00AM – 6:00PM ET, excluding holidays
Call the preferred specialty pharmacy with questions about VANFLYTA prescriptions and patient support.
Biologics (1-800-850-4306) or Onco360 (1-877-662-6633)
